Senores Subsidiaries Plan ₹43 Cr Capacity Expansion

Date: October 29, 2026

Board Meeting Outcomes

The Board of Directors of Senores Pharmaceuticals Limited, at their meeting held on October 29, 2026, noted and approved capacity expansion plans for three subsidiary companies. The total estimated investment for these expansions is ₹43.00 crores. All expansions are planned to be completed by the end of March 2027.

Expansion / Capex

Havix Group INC, USA (Subsidiary)

• Existing Capacity: 1.2 Billion units per annum
• Enhanced Capacity: 2.0 Billion units per annum
• Capacity Addition: 0.8 Billion units
• Estimated Cost: ₹18.00 Crores
• Existing Capacity Utilisation: Approximately 50-70%
• Mode of Financing: Internal accruals and IPO proceeds
• Rationale: To meet the existing and future demand

Apnar Pharma Private Limited, India (Subsidiary)

• Existing Capacity: 0.5 Billion units per annum
• Enhanced Capacity: 1.2 Billion units per annum
• Capacity Addition: 0.7 Billion units
• Estimated Cost: ₹20.00 Crores

Ratnatris Pharmaceuticals Private Limited (Subsidiary)

• New Line: Addition of a new Prefilled Syringe (PFS) line
• New Capacity: 2.7 Million units per annum
• Estimated Cost: ₹5.00 Crores